Patents by Inventor Shanthi ADIMOOLAM

Shanthi ADIMOOLAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
    Patent number: 9408816
    Abstract: Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: August 9, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Shanthi Adimoolam, Joseph J. Buggy, Darren Magda, Richard Miller
  • METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY
    Publication number: 20080153877
    Abstract: Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.
    Type: Application
    Filed: December 7, 2007
    Publication date: June 26, 2008
    Applicant: PHARMACYCLICS, INC.
    Inventors: Shanthi ADIMOOLAM, Joseph J. BUGGY, Darren MAGDA, Richard MILLER